Cargando…

Early stage and long term treatment of multiple sclerosis with interferon-β

Multiple sclerosis (MS) affects young adults during the most productive years of their lives, and until recently many neurologists were limited to treating symptoms and attacks without any ability to alter the disease course. The 1990s ushered in an era of possibility with the approval of three inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Applebee, Angela, Panitch, Hillel
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726076/
https://www.ncbi.nlm.nih.gov/pubmed/19707414
_version_ 1782170563915022336
author Applebee, Angela
Panitch, Hillel
author_facet Applebee, Angela
Panitch, Hillel
author_sort Applebee, Angela
collection PubMed
description Multiple sclerosis (MS) affects young adults during the most productive years of their lives, and until recently many neurologists were limited to treating symptoms and attacks without any ability to alter the disease course. The 1990s ushered in an era of possibility with the approval of three interferon-beta (IFNβ) therapies for the treatment of MS. Though the mechanism of action of these agents is not completely understood, it is clear they reduce magnetic resonance imaging (MRI) activity as well as improve clinical outcomes. The principal randomized, blinded, multicenter trials of IFNβ all point to the need for early treatment soon after the diagnosis of MS is made. Efficacy has also been shown in patients treated after a first demyelinating event. Data on IFNβ in the treatment of secondary progressive MS (SPMS) is not impressive, although it shows some benefit in SPMS patients who continue to experience MRI activity and clinical relapses, signifying a continued inflammatory component to their disease. There has been no proven efficacy of IFNβ in the treatment of primary progressive MS (PPMS). The IFNβ therapies are generally well tolerated with a favorable side effect profile. Despite benefits in MRI and clinical measures such as relapse rates and Expanded Disability Status Scale progression, patients continue to exhibit clinical progression and radiological atrophy, pointing to confounding factors and perhaps multiple etiologies of a disease that is not yet fully understood. In addition, the subject of neutralizing antibodies has recently assumed importance. The significance of these on treatment efficacy is uncertain, and until a universally accepted reliable assay is adopted, the decision to change treatment continues to rely on the clinical interpretation of the patient’s history and physical examination. Additional recommendations for management of patients, informed by the best available evidence, are also presented.
format Text
id pubmed-2726076
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-27260762009-08-25 Early stage and long term treatment of multiple sclerosis with interferon-β Applebee, Angela Panitch, Hillel Biologics Review Multiple sclerosis (MS) affects young adults during the most productive years of their lives, and until recently many neurologists were limited to treating symptoms and attacks without any ability to alter the disease course. The 1990s ushered in an era of possibility with the approval of three interferon-beta (IFNβ) therapies for the treatment of MS. Though the mechanism of action of these agents is not completely understood, it is clear they reduce magnetic resonance imaging (MRI) activity as well as improve clinical outcomes. The principal randomized, blinded, multicenter trials of IFNβ all point to the need for early treatment soon after the diagnosis of MS is made. Efficacy has also been shown in patients treated after a first demyelinating event. Data on IFNβ in the treatment of secondary progressive MS (SPMS) is not impressive, although it shows some benefit in SPMS patients who continue to experience MRI activity and clinical relapses, signifying a continued inflammatory component to their disease. There has been no proven efficacy of IFNβ in the treatment of primary progressive MS (PPMS). The IFNβ therapies are generally well tolerated with a favorable side effect profile. Despite benefits in MRI and clinical measures such as relapse rates and Expanded Disability Status Scale progression, patients continue to exhibit clinical progression and radiological atrophy, pointing to confounding factors and perhaps multiple etiologies of a disease that is not yet fully understood. In addition, the subject of neutralizing antibodies has recently assumed importance. The significance of these on treatment efficacy is uncertain, and until a universally accepted reliable assay is adopted, the decision to change treatment continues to rely on the clinical interpretation of the patient’s history and physical examination. Additional recommendations for management of patients, informed by the best available evidence, are also presented. Dove Medical Press 2009 2009-07-13 /pmc/articles/PMC2726076/ /pubmed/19707414 Text en © 2009 Applebee and Panitch, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Applebee, Angela
Panitch, Hillel
Early stage and long term treatment of multiple sclerosis with interferon-β
title Early stage and long term treatment of multiple sclerosis with interferon-β
title_full Early stage and long term treatment of multiple sclerosis with interferon-β
title_fullStr Early stage and long term treatment of multiple sclerosis with interferon-β
title_full_unstemmed Early stage and long term treatment of multiple sclerosis with interferon-β
title_short Early stage and long term treatment of multiple sclerosis with interferon-β
title_sort early stage and long term treatment of multiple sclerosis with interferon-β
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726076/
https://www.ncbi.nlm.nih.gov/pubmed/19707414
work_keys_str_mv AT applebeeangela earlystageandlongtermtreatmentofmultiplesclerosiswithinterferonb
AT panitchhillel earlystageandlongtermtreatmentofmultiplesclerosiswithinterferonb